Beranda › Karsinoma Neuroendokrin › New York
Uji klinis Karsinoma Neuroendokrin di New York
6 studi untuk Karsinoma Neuroendokrin mencari peserta di lokasi di New York.
Kota di New York
Teks studi resmi (Bahasa Inggris)
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Icahn School of Medicine at Mount Sinai, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07080242A Study of Armored CAR T Cells in People With Cancer
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- dan 1 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07783477A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- NYU Langone Health, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07488923A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
- Clinical Research Alliance, Inc, Westbury
- dan 1 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, New York
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07129252A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Columbia University Medical Center - Herbert Irving Pavilion, New York
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT07174583Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.